Neurophth Biotechnology
Business Services · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Optics Valley Biological City No. 666 c2...Phone Number
+86 2765524119Website
www.neurophth.comRevenue
$101.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Neurophth Biotechnology
Founded in 2016 and based out of China, Neurophth Biotechnology is a genetic medicines development company with a focus on ocular diseases.Explore more
Neurophth Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurophth Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Neurophth Biotechnology launches new products
Congratulate Masked Content for being promoted to Masked Content at Neurophth Biotechnology
Website visits: Recent activity has been detected on your website
Check if Neurophth Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neurophth Biotechnology had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Neurophth Biotechnology recently announced quarterly report
Neurophth Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Neurophth Biotechnology is spiking on competitors!
Funding: Get notified immidiatlly once Neurophth Biotechnology has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Neurophth Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neurophth Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neurophth Biotechnology.
Neurophth Biotechnology financials insights
Gather financial insights about Neurophth Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$18.4M
2021
Series B
$61.9M
2023
Series C
$95M
Neurophth Biotechnology Tech Stack
A closer look at the technologies used by Neurophth Biotechnology
Most Recent Scoops
Event
Events
Funding
Left Company
Executive Move
Neurophth Biotechnology has announced that Xin Zhang, Chief Operations Officer & Chief Medical Officer, has left the organization.
New Hire
Executive Move
Neurophth Biotechnology News & Media
10 biotech companies leading innovation in the Asia-Pacific region - Labiotech
Take a closer look at 10 Asia-Pacific companies leading innovation in the biopharma industry in the region.VGXI Celebrates Successful Completion of Neurophth Engineering Run to Advance Ocular Gene Therapy Candidate
VGXI, Inc. proudly announces the successful completion of the engineering run for plasmid DNA used in Neurophth's AAV ocular gene therapy. CONROE, Texas , Nov. 14, 2023 /PRNewswire-PRWeb/ -- VGXI, Inc., a leading contract development and manufacturing organization (CDMO) specializing in...Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
The groundbreaking ADOA treatment marks a significant breakthrough in the field WUHAN, China and SAN DIEGO, Sept. 6, 2023 /PRNewswire/ -- On September 6, 2023, Neurophth Therapeutics (hereinafter referred to as "Neurophth"), a leader in in-vivo gene therapy for ophthalmic diseases in...Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a Phase I/II, multi-region, multi-center, single-arm, open-labeled, dose-finding study aimed at evaluating the safety, tolerability, and efficacy of NFS-02 i
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Neurophth Biotechnology
Sign Up For FreeTo access detailed company insights
Founded in 2016 and based out of China, Neurophth Biotechnology is a genetic medicines development company with a focus on ocular diseases.... Read More
